Interleukin-1 receptor antagonist prevents expression of the metalloproteinase-generated neoepitope vdipen in antigen-induced arthritis

Arthritis and Rheumatism

Volumn 41, Issue 4, 1998, Pages 647-656

  Van Meurs, Joyce B J ^a   Van Lent, Peter L E M ^a   Singer, Irwin I ^b   Bayne, Ellen K ^b   Van De Loo, Fons A J ^a   Van Den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METALLOPROTEINASE; PROTEOGLYCAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTHRITIS; ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL DEATH; IMMUNOPATHOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOGLYCAN SYNTHESIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS; ARTHRITIS; BONE REGENERATION; CARTILAGE; EPITOPES; IMMUNOHISTOCHEMISTRY; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; KNEE JOINT; MALE; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PROTEOGLYCANS; RECEPTORS, INTERLEUKIN-1; SIALOGLYCOPROTEINS;

EID: 0031947366     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199804)41:4<647::AID-ART11>3.0.CO;2-T     Document Type: Article

References (39)

1. Sandy JD, Neame PJ, Boynton RE, Flannery CR. Catabolism of aggrecan in cartilage explants: identification of a major cleavage site within the interglobular domain. J Biol Chem 1991;266: 8683-5.
2. Flannery CR, Lark JD, Sandy JD. Identification of a stromelysin cleavage site within the interglobular domain of human of aggrecan: evidence for proteolysis at this site in vivo in human cartilage. J Biol Chem 1992;267:1008-14.
3. Fosang AJ, Neame PJ, Last K, Hardingham TE, Murphy G, Hamilton JA. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases and cathepsin B. J Biol Chem 1992;267:19470-4.
4. Fosang AJ, Last K, Knäuper V, Murphy G, Neame PJ. Degradation of cartilage aggrecan by collagenase 3 (MMP-13). FEBS Lett 1996;380:17-20.
5. Fosang AJ, Last K, Knäuper V, Neame PJ, Murphy G, Hardingham TE, et al. Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. Biochem J 1993;295:273-6.
6. Lohmander LS, Neame PJ, Sandy JD. The structure of aggrecan fragments in human synovial fluid: evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum 1993;36:1214-22.
7. Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, et al. Aggrecan degradation in human cartilage: evidence for both metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 1997; 100:93-106.
8. Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A 1986;83:8749-53.
9. Dingle JT, Page Thomas PH, King B, Bard DR. In vivo studies of articular tissue damage mediated by catabolin/interleukin 1. Ann Rheum Dis 1987;46:527-33.
10. Van de Loo AAJ, van den Berg WB. Effects of murine recombinant interleukin 1 on synovial joints in mice: measurements of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 1990;49:238-45.
11. Tyler JA. Chondrocyte-mediated depletion of articular cartilage proteoglycans in vitro. Biochem J 1985;225:493-507.
12. Van den Berg WB, van de Loo AAJ, Zwarts WA, Otterness I. Effects of murine recombinant interleukin 1 on intact homologous articular cartilage: a quantitative and autoradiographic study. Ann Rheum Dis 1988;47:855-63.
13. Pratta MA, Di Meo TM, Ruhl DM, Arner EC. Effects of interleukin-1-beta and tumor necrosis factor-alpha on cartilage proteoglycan metabolism in vitro. Agents Actions 1989;27:250-3.
14. Schnyder J, Payne T, Dinarello CA. Human monocyte or recombinant interleukin Is are specific for the secretion of a metalloproteinase from chondrocytes. J Immunol 1987;138:496-503.
15. Andrews HJ, Plumpton TA, Harper GP, Cawston HE. A synthetic peptide metalloproteinase inhibitor, but not TIMP, prevents the breakdown of proteoglycan within articular cartilage in vitro. Agents Actions 1992;37:147-54.
16. Seed MP, Ismaiel S, Cheung CY, Thomson TA, Gardner CR, Atkins RM, et al. Inhibition of interleukin 1β induced rat and human cartilage degradation in vitro by the metalloproteinase inhibitor U27391. Ann Rheum Dis 1993;52:37-43.
17. Mort JS, Dodge GR, Roughley PJ, Liu J, Finch SJ, Dipasquale G, et al. Direct evidence for active metalloproteinases mediating matrix degradation in interleukin 1-stimulated human articular cartilage. Matrix 1993;13:95-102.
18. Buttle DJ, Handley CJ, Ilic MZ, Saklatvala J, Murata M, Barrett AJ. Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases: evidence for two converging pathways of chondrocytemediated proteoglycan degradation. Arthritis Rheum 1993;36: 1709-17.
19. Loulakis P, Shrikhande A, Davis G, Maniglia CA. N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1 treated articular cartilage cultures. Biochem J 1992; 284:589-93.
20. Witt M, Fosang AJ, Hughes CE, Hardingham TE. Changes in the pattern of aggrecan cleavage in cartilage expiants following stimulation with IL-1 alpha or retinoate and inhibition of cleavage by a metalloproteinase inhibitor [abstract]. Trans Orthop Res Soc 1995;20:122.
21. Singer II, Kawka DW, Bayne EK, Donatelli AA, Weidner JR, Williams HR, et al. VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis. J Clin Invest 1995;95:2178-86.
22. Van den Berg WB, Kruijsen MWM, van de Putte LA, Beusekon HJ, Sluis-van de Pol M, Zwarts W. Antigen-induced and zymosan-induced arthritis in mice: studies on in vivo cartilage proteoglycan synthesis and chondrocyte death. Br J Exp Pathol 1981;62:308-16.
23. Kruijsen MWM, van den Berg WB, van de Putte LBA. Influence of the severity and duration of murine antigen-induced arthritis on cartilage proteoglycan synthesis and chondrocyte death. Arthritis Rheum 1985;28:813-9.
24. Van de Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995;38:164-72.
25. Van Lent PLEM, van de Loo AAJ, Holthuysen AEM, van den Bersselaar LAM, Vermeer H, van den Berg WB. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatol 1995; 22:2250-8.
26. Joosten LAB, Helsen MMA, van de Loo AAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. Arthritis Rheum 1996;39:797-809
27. 3H-acetate. Rheumatol Int 1986;6:273-81.
28. Van der Kraan PM, de Lange J, Vitters EL, van Beuningen HM, van Osch JVM, van Lent PLEM, et al. Analysis of changes in proteoglycan content in murine articular cartilage using image analysis. Osteoarthitis Cartilage 1994;2:207-14.
29. Lark MW, Williams H, Hoernner LA, Weidner J, Ayala JM, Harper CF, et al. Quantification of a matrix metalloproteinase-generated aggrecan G1 fragment using monospecific anti-peptide serum. Biochem J 1995;307:245-52.
30. Shu S, Ju G, Fan L. The glucose oxidase-DAB nickel method in peroxidase histochemistry of the nervous system. Neurosci Lett 1988;85:169-71.
31. Buttle JD. Lysosomal cysteine endopeptidases in the degradation of cartilage and bone. In: Davies ME, Dingle JT, editors. Immunopharmacology of joints and connective tissue. San Diego: Academic Press; 1994. p. 225-43.
32. Velvart M, Fehr K, Baici A. Degradation in vivo of articular cartilage in rheumatoid arthritis by leukocyte elastase from polymorphonuclear leukocytes. Rheumatol Int 1981;1:121-30.
33. Schalkwijk J, Joosten LAB, van den Berg WB, van de Putte LBA. Antigen induced arthritis in beige mice. Ann Rheum Dis 1990;49: 607-10.
34. Fosang AJ, Last K, Maciewicz RA. Aggrecan is degraded by metalloproteinases in human arthritis: evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest 1996;98:2292-9.
35. McDonnell J, Hoerrner LA, Lark MW, Harper C, Dey T, Lobner J, et al. Recombinant human interleukin-1β-induced increase in levels of proteoglycans, stromelysin, and leukocytes in rabbit synovial fluid. Arthritis Rheum 1992;35:799-805.
36. Pasternak RD, Hubbs SJ, Caccese RG, Marks RL, Conaty JM, Dipasquale G. Interleukin-1 stimulates the secretion of proteoglycan- and collagen-degrading proteases by rabbit articular chondrocytes. Clin Immunol Immunopathol 1986;41:351-67.
37. Henderson B, Lewthwaite J. Cytokines and cartilage loss in rheumatoid arthritis and osteoarthritis. Curr Med Lit 1991;10:3-10.
38. Lewthwaite J, Blake SM, Hardingham TE, Warden PJ, Henderson B. The effect of recombinant human interleukin 1 receptor antagonist on the induction phase of antigen induced arthritis in the rabbit. J Rheumatol 1994;21:467-72.
39. Hollander AP, Dieppe PA, Atkins RM, Elson CJ. Hypothesis: cartilage catabolic cofactors in human arthritis. J Rheumatol 1993;20:223-4.